Trabecular micro-bypass stent implantation during small-incision @entity231 surgery for open-angle glaucoma or XXXX : Long-term results.

@entity1 @entity231 @entity9998 @entity726 @entity2790 @entity551
PURPOSE: To evaluate long-term safety and efficacy of iStent trabecular micro-bypass stent implantation during @entity231 surgery in @entity1 with primary open-angle, @entity9998 , @entity2790 , or secondary or post-traumatic @entity726 . SETTING: AaM Augenklinik am Marienplatz, Munich, Germany. DESIGN: Prospective, open-label, non-randomized study. METHODS: Preoperative and postoperative evaluations included intra-ocular pressure (IOP), @entity551 medication use, cup/disc ratio, corrected-distance visual acuity (CDVA), complications, and adverse events. RESULTS: A single trabecular micro-bypass stent was implanted through the same temporal, limbal incision used for @entity231 surgery via phacoemulsification in a consecutive series of 62 eyes of 43 @entity1 . To date, a total of 41 eyes have been followed for 3  years postoperatively, whereas long-term postoperative follow-up on the remaining @entity1 is ongoing. Mean preoperative IOP was 24.1      6.9 mm Hg on a mean of 1.8 medications (  0.9). Analyses of eyes with no secondary surgical intervention showed mean IOP reduction to 14.8      4.2 mm Hg at 12  months (n  =  61), 14.5      2.2 mm Hg at 24  months (n  =  42), and 14.9      2.3 mm Hg at 36  months (n  =  39). Medications were eliminated in 74% of eyes at 36  months. Five eyes, 4 with previous @entity726 surgeries and 1 with @entity9998 , required additional @entity726 surgery after stent implantation. No intra-operative or postoperative complications typically seen with conventional @entity726 surgeries occurred after stent implantation. At 36  months, CDVA was 20/40 or better in 38 eyes (93%). CONCLUSION: Trabecular micro-bypass stent implantation during @entity231 surgery was safe and effective in @entity1 with @entity2790 or @entity726 as measured by a sustained reduction in IOP and medication use and an excellent safety profile through 3  years after surgery. FINANCIAL DISCLOSURES: Dr. Neuhann has no financial or proprietary interest in any material or method mentioned. Glaukos Corp. provided editorial assistance in the preparation of the manuscript.
